









市場行情
/
股票
/
nasdaq-kpti
/

Karyopharm Therapeutics Inc

KPTI

6.940USD

+0.570+8.95%

收盤 12/19, 16:00（美東）報價延遲15分鐘

60.39M總市值

虧損本益比TTM



Karyopharm Therapeutics Inc

6.940

+0.570+8.95%

概覽公司財務分析

概覽

公司

財務

分析

關於 Karyopharm Therapeutics Inc 公司

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Karyopharm Therapeutics Inc簡介



公司代碼KPTI

公司名稱Karyopharm Therapeutics Inc

上市日期Nov 06, 2013

CEOPaulson (Richard A)

員工數量279

證券類型Ordinary Share

年結日Nov 06

公司地址85 Wells Avenue

城市NEWTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02459

電話16176580600

網址https://karyopharm.com/

公司代碼KPTI

上市日期Nov 06, 2013

CEOPaulson (Richard A)

Karyopharm Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Michael Mano, J.D.

Senior Vice President, General Counsel, Secretary

55.93K

+355.57%

Mr. Stuart Poulton

Executive Vice President, Chief Development Officer

48.29K

+460.88%

Dr. Reshma Rangwala, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

7.24K

+8.01%

Mr. Barry E. Greene

Lead Independent Director

907.00

Ms. Sohanya Cheng

Executive Vice President, Chief Commercial Officer

Mr. Garen G. Bohlin

Independent Director

Mr. Chen Schor, CPA

Independent Director

Mr. Richard A. Paulson

President, Chief Executive Officer, Director

Mr. Brendan Strong

Senior Vice President - Investor Relations and Corporate Communications

Ms. Lori Macomber, CPA

Executive Vice President, Chief Financial Officer, Treasurer

名稱

名稱/職務

職務

持股

持股變動

Mr. Michael Mano, J.D.

Senior Vice President, General Counsel, Secretary

55.93K

+355.57%

Mr. Stuart Poulton

Executive Vice President, Chief Development Officer

48.29K

+460.88%

Dr. Reshma Rangwala, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

7.24K

+8.01%

Mr. Barry E. Greene

Lead Independent Director

907.00

Ms. Sohanya Cheng

Executive Vice President, Chief Commercial Officer

Mr. Garen G. Bohlin

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

T. Rowe Price Investment Management, Inc.

13.51%

Opaleye Management Inc.

5.57%

J. Wood Capital Advisors LLC

4.60%

Adage Capital Management, L.P.

2.47%

The Vanguard Group, Inc.

2.39%

其他

71.45%

持股股東

佔比

T. Rowe Price Investment Management, Inc.

13.51%

Opaleye Management Inc.

5.57%

J. Wood Capital Advisors LLC

4.60%

Adage Capital Management, L.P.

2.47%

The Vanguard Group, Inc.

2.39%

其他

71.45%

股東類型

持股股東

佔比

Investment Advisor

18.95%

Hedge Fund

9.84%

Corporation

4.60%

Investment Advisor/Hedge Fund

2.40%

Individual Investor

2.32%

Venture Capital

0.92%

Research Firm

0.71%

Bank and Trust

0.06%

其他

60.18%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

251

4.11M

24.14%

-1.36M

2025Q2

284

4.20M

48.66%

-1.75M

2025Q1

308

4.25M

49.43%

-1.53M

2024Q4

324

4.68M

55.67%

-1.51M

2024Q3

341

4.98M

60.06%

-2.16M

2024Q2

356

5.56M

67.54%

-2.08M

2024Q1

352

5.60M

72.46%

-1.99M

2023Q4

354

5.60M

73.31%

-2.02M

2023Q3

365

5.88M

77.33%

-1.69M

2023Q2

380

6.19M

81.48%

-2.04M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

T. Rowe Price Investment Management, Inc.

728.77K

8.4%

+589.12K

+421.87%

Jun 30, 2025

J. Wood Capital Advisors LLC

458.13K

5.28%

Apr 10, 2025

Adage Capital Management, L.P.

421.32K

4.86%

Jun 30, 2025

The Vanguard Group, Inc.

518.27K

5.98%

+7.97K

+1.56%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

184.85K

2.13%

-3.16K

-1.68%

Jun 30, 2025

Catalio Capital Management, LP

146.01K

1.68%

-9.61K

-6.17%

Jun 30, 2025

Avidity Partners Management LP

134.57K

1.55%

Jun 30, 2025

Marshall Wace LLP

128.45K

1.48%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.01%

Global X Russell 2000 Covered Call ETF

Invesco NASDAQ Future Gen 200 ETF

Fidelity Enhanced Small Cap ETF

Goldman Sachs ActiveBeta US Small Cap Equity ETF

ProShares Hedge Replication ETF

iShares Russell 2000 ETF

ProShares UltraPro Russell2000

Proshares Ultra Russell 2000

iShares Russell 2000 Growth ETF

iShares Micro-Cap ETF

佔比0.01%

Global X Russell 2000 Covered Call ETF

佔比0%

Invesco NASDAQ Future Gen 200 ETF

佔比0%

Fidelity Enhanced Small Cap ETF

佔比0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0%

ProShares Hedge Replication ETF

佔比0%

iShares Russell 2000 ETF

佔比0%

ProShares UltraPro Russell2000

佔比0%

Proshares Ultra Russell 2000

佔比0%

iShares Russell 2000 Growth ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

公告日期

類型

比率

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

常見問題

Karyopharm Therapeutics Inc的前五大股東是誰？



Karyopharm Therapeutics Inc的前五大股東如下：
T. Rowe Price Investment Management, Inc.
持有股份：728.77K
佔總股份比例：8.40%。
J. Wood Capital Advisors LLC
持有股份：458.13K
佔總股份比例：5.28%。
Adage Capital Management, L.P.
持有股份：421.32K
佔總股份比例：4.86%。
The Vanguard Group, Inc.
持有股份：518.27K
佔總股份比例：5.98%。
BlackRock Institutional Trust Company, N.A.
持有股份：184.85K
佔總股份比例：2.13%。